Skip to main content
Fig. 10 | BMC Musculoskeletal Disorders

Fig. 10

From: Treatment of critically sized femoral defects with recombinant BMP-2 delivered by a modified mPEG-PLGA biodegradable thermosensitive hydrogel

Fig. 10

Expression of bone regeneration markers in femoral defects after treatment. a After 12-week treatments, the indicated samples were examined for the expression of COL1A1, ALP and OC by Western blot analysis. After normalization with the β-actin content, the relative expression levels of COL1A1, ALP and OC were shown in (b, c and d). Healthy: healthy femora, *P < 0.05 compared to the untreated group

Back to article page